By: 28 April 2017
Generating improvement in spinal cord injuries

The use of oligodendrocyte progenitor cells to treat spinal cord injuries has shown promising results in early clinical trials at Rush University Medical Center in the USA, offering new hope for regenerative medicine

A new therapy to treat spinal cord injuries in people who have lost all motor function and feeling below the location of the injury shows motor function improvement at six months and nine months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced in January in a conference held by Asterias Biotherapeutics, the biotechnology company that manufactures the treatment.

“With these patients, we are seeing what we believe are meaningful improvements in their ability to use their arms, hands and fingers at six months and nine months following AST-OPC1 administration,” said Richard Fessler, professor in the department of neurological surgery at Rush University Medical Center. Fessler is the lead investigator of the study, known as SCiStar Phase 1/2a, that is evaluating AST-OPC1 treatment, and Rush is one of six centres in the USA currently studying this new approach.

AST-OPC1 cells are created from embryonic stem cells by carefully converting them into oligodendrocyte progenitor cells. Found in the brain and spinal cord, these cells support the healthy functioning of nerve cells, and can potentially make poorly functioning nerves work better.

For this study, a total of six patients were enrolled and treated with 10 million AST-OPC1 cells. Five of the six patients have now completed a six-month follow-up, and three of those have completed a nine-month follow-up.


This can dramatically improve quality of life

“Recovery of upper extremity motor function is critically important to patients with complete cervical spinal cord injuries, since this can dramatically improve quality of life and their ability to live independently,” said Fessler.

“The results to date are quite encouraging, and we look forward to initiating discussions with the FDA in mid-2017 to begin to determine the most appropriate clinical and regulatory path forward for this innovative therapy,” said Steve Cartt, chief executive officer of Asterias.

More than 17,000 people in the USA suffer a severe, debilitating spinal cord injury each year. These injuries can be devastating to quality of life and ability to function independently. Lifetime healthcare costs for these patients can cost millions. Improvements in arm, hand and finger functional capabilities can result in lower healthcare costs, significant improvements in quality of life, increased ability to engage in activities of daily living, and increased independence.


Results see improvements in motor function

The study is measuring improvements in upper extremity motor function using the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) scale, which is widely used to quantify functional status of patients with spinal cord injuries. The latest results include the following highlights.

Upper extremity motor score

All of the five patients who have completed at least six months of follow-up saw their early improvements in motor score at three months maintained or further increased through their most recent data point (six months or nine months, depending on the most recent data available for each patient).


Motor level improvement

All five of the patients completing at least six months of follow up, as of the date of each patient’s last follow-up visit, had achieved at least a one motor level improvement (using the ISNCSCI scale) over baseline on at least one side, and two of the five had achieved two motor levels over baseline on at least one side, with one of these patients achieving a two motor level improvement on both sides.


Matched historical control data

Asterias and experts in the spinal cord injury field have developed a set of matched historical control data for both upper extremity motor score and motor level improvement to clearly document expected spontaneous recovery in untreated patients for comparison with results seen in patients treated with AST-OPC1. The key results from this analysis, which show a meaningful difference in the motor function recovery seen to date in patients treated with AST-OPC1, was presented during the conference.


The trial results to date continue to reveal a positive safety profile for AST-OPC1. There have been no serious adverse events related to AST-OPC1, and data from the study indicate that AST-OPC1 can be safely administered to patients in the subacute period after severe cervical spinal cord injury.


Study locations planned to double

The SCiStar trial is an open-label, single-arm trial testing three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in as many as 35 patients with sub-acute, C-5 to C-7, motor complete (AIS-A or AIS-B) cervical SCI. These individuals have essentially lost all movement below their injury site and experience severe paralysis of the upper and lower limbs. AIS-A patients have lost all motor and sensory function below their injury site, while AIS-B patients have lost all motor function but may retain some minimal sensory function below their injury site.

AST-OPC1 is being administered 14 to 30 days post-injury. Patients will be followed by neurological exams and imaging procedures to assess the safety and activity of the product.


Source: Rush University Medical Center

Picture credit: Credit: Rush Photo Group

For more information on Rush University Medical Center, visit